“The ultimate goal for wildlife rehabilitation is that animal is to be released. You want that animal to be a successful ...

In April 2025, the FDA announced plans to shift biomedical research for monoclonal antibodies and other medications away from ...

If Japan adopted U.S. policies that promote generic utilization, it could pay more for new, innovative drugs without ...

In this piece, senior staff columnist Sierra O’Neil examines whether old-fashioned exams in college are truly the best way to ...

One of the hardest entrance exams in the world for aspiring medical students is the Graduate Medical School Admissions Test, ...

Why personalized gene editing, genetic resurrections and embryo scoring made our list. Earlier this week, MIT Technology Review published its annual list of Ten Breakthrough Technologies. As always, ...

Emily A. Buddle has received funding from the Department of Primary Industries and Regions South Australia, the Australian Research Council and Meat and Livestock Australia. She is currently an ...

CNBC’s “Closing Bell Overtime” team discusses why the biotech recovery may continue into 2026 with Salveen Richter, lead U.S. biotech analyst at Goldman Sachs Research. Got a confidential news tip? We ...

Allison DeAngelis is the East Coast biotech and venture capital reporter at STAT, reporting where scientific ideas and money meet. She is also co-host of the weekly biotech podcast, The Readout Loud.

The first part of the EU’s Biotech Act has been published. The act, which is mainly focused on health, also touches on food innovation and the regulation around novel foods. Overall, it’s a mixed bag.

When you purchase through links on our site, we may earn an affiliate commission. Here’s how it works. Healthcare and biotech stocks have had a rough run since the giddy heights of the Covid pandemic.